In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according to results from a retrospective cohort study. Compared with white women, Black women with TNBC were less likely to achieve pCR (OR 0.89, 95% CI 0.83-0.95, […]
A Win for Trabectedin in High-Grade Myxoid Liposarcoma?
Neoadjuvant trabectedin (Yondelis) for high-grade myxoid liposarcoma (HG-MLPS) demonstrated noninferiority to the long-time standard of anthracycline-ifosfamide (AI), according to new data from a previously completed trial. Standard therapy was associated with twice as many recurrences as compared with trabectedin, translating into a 40% reduction in the hazard for disease-free survival (DFS) in favor of trabectedin. […]
Delaying Esophageal Cancer Surgery After Neoadjuvant CRT Fails in Trial
Prolonging the time to surgery following neoadjuvant chemoradiotherapy (CRT) for esophageal cancer failed to improve histological complete response rates and may even worsen overall survival (OS), according to results from the randomized NeoRes II study. Among the subset with adenocarcinoma, complete response rates were not significantly better with the prolonged surgical approach (10-12 weeks) compared […]
High Rates of pCR With Novel Neoadjuvant Combination for Breast Cancer
SAN ANTONIO — A novel neoadjuvant regimen for HER2-negative breast cancer doubled the pathologic complete response (pCR) rate as compared with standard chemotherapy, a small phase II study showed. Across various breast cancer receptor signatures, pCR rates ranged from 36% to 53% with the combination of paclitaxel, the PD-1 inhibitor cemiplimab (Libtayo), and the investigational […]
Pre-Op Axitinib Helps for Partial Nephrectomy of Complex Renal Tumors
SAN DIEGO — Use of neoadjuvant axitinib (Inlyta) resulted in significant reductions in tumor size and complexity, enabling partial nephrectomy in a cohort of patients with highly complex renal masses in whom the procedure would ordinarily not be feasible, according to an interim analysis from a small phase II trial. A course of the tyrosine […]
Study Suggests Potential to Skip Surgery for Selected Breast Cancer Patients
Women who chose not to have surgery after a pathologic complete response (pCR) to neoadjuvant therapy for early HER2-positive or triple-negative breast cancer (TNBC) had no recurrences during the first 2 years of follow-up, a small prospective study showed. Overall, 31 of 50 (62%) women had no evidence of residual disease by image-guided vacuum-assisted core […]
Pre-Op Atezolizumab Promising in Muscle-Invasive Bladder Cancer
The use of a checkpoint inhibitor combined with chemotherapy in the neoadjuvant setting appeared to be effective for patients with muscle-invasive bladder cancer (MIBC), according to results from a phase II trial. Among 39 patients, the addition of the PD-L1 inhibitor atezolizumab (Tecentriq) to gemcitabine and cisplatin resulted in a non-muscle-invasive downstaging rate of 69% […]